Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide

Drug Delivery

Volumn 20, Issue 7, 2013, Pages 269-276

  Verma, Parmanand ^a   Gupta, Roop Narayan ^a   Jha, Arvind Kumar ^b   Pandey, Ravishankar ^c  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b Shri Shankaracharya Group of Institution   (India)

^c GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Glaucoma; Intra ocular pressure; Nanoprecipitation; Ocular; Topical

Indexed keywords

ACETAZOLAMIDE; ACETONE; ADRENALIN HYDROGEN TARTRATE; EUDRAGIT; METHANOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; SURFACE CHARGE; SURFACE PROPERTY; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ACETAZOLAMIDE; ACRYLIC RESINS; ADMINISTRATION, OPHTHALMIC; ANIMALS; BIOLOGICAL AVAILABILITY; CARBONIC ANHYDRASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; MODELS, CHEMICAL; NANOPARTICLES; PARTICLE SIZE; RABBITS; TEMPERATURE; TIME FACTORS;

EID: 84884582583     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.834417     Document Type: Article

References (37)

1. Aggarwal D, Pal D, Mitra AK, Kaur IP. (2007). Study of the extent of ocular absorption of ACZ from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm 338:21-6.
2. Aksungur P, Demirbilek M, Denkbas- EB, et al. (2011). Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Rel 151:286-94.
3. Arthur S, Cantor LB. (2011). Update on the role of alpha-agonists in glaucoma management. Exp Eye Res 93:271-83.
4. Baba K, Tanaka Y, Kubota A, et al. (2011). A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye. J Control Rel 153:278-87.
5. Behki R, Damji KF, Crichton A. (2007). Canadian perspectives in glaucoma management: the role of central corneal thickness. Can J Ophthalmol 42:66-74.
6. Castelli F, Messina C, Sarpietro M, et al. (2002). Flurbiprofen release from eudragit RS and RL aqueous nanosuspensions: a kinetic study by DSC and dialysis experiments. AAPS PharmSciTech 3:1-8.
7. Castelli F, Messina C, Sarpietro MG, et al. (2003). Eudragit as controlled release system for anti-inflammatory drugs: a comparison between DSC and dialysis experiments. Thermochim Acta 400: 227-34.
8. Costa VP, Braga MEM, Duarte CMM, et al. (2010). Anti-glaucoma drug-loaded contact lenses prepared using supercritical solvent impregnation. J Supercrit Fluids 53:165-73.
9. Das S, Suresh PK, Desmukh R. (2010). Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomed Nanotechnol 6:318-23.
10. Dillen K, Vandervoort J, Mooter G, Ludwig A. (2006). Evaluation of ciprofloxacin loaded Eudragit- RS100 or RL100/PLGA nanoparticles. Int J Pharm 314:72-82.
11. Eid TM. (2011). Primary lens extraction for glaucoma management: a review article. Saudi J Ophthalmol 25:337-45.
12. Fessi H, Puisieux F, Devissaguet J, et al. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-4.
13. Granero GE, Maitre MM, Garnero C, Longhi MR. (2008). Synthesis, characterization and in vitro release studies of a new acetazolamide- HP-b-CD-TEA inclusion complex. Eur J Med Chem 43:464-70.
14. Haeringen NJV. (1981). Clinical biochemistry of tears. Surv Ophthalmol 26:84-95.
15. Hao S, Wang B, Wang Y, et al. (2013). Preparation of Eudragit L 100-55 enteric nanoparticles by a novel emulsion diffusion method. Colloids Surf B 108:127-33.
16. ICH Harmonized Tripartite Guidelines (1996). Validation of analytical procedure: text and methodology Q2 (R1).
17. Indian Pharmacopoeia. (2007). Acetazolamide. Ministry of Health & Family Welfare, Government of India. Volume II. Ghaziabad, India. 65 p.
18. Kaur IP, Singh M, Kanwar M. (2000). Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm 199:119-27.
19. Kaur IP, Smitha R, Aggarwal D, Kapil M. (2002). Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm 248:1-14.
20. Liang SYW, Lee GA, Shields D. (2009). Self-tonometer in glaucoma management-past, present and future. Surv Ophthalmol 54:450-62.
21. Lindenberg M, Kopp S, Dressman JB. (2004). Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-78.
22. Mora MJ, Longhi MR, Granero GE. (2010). Synthesis and characterization of binary and ternary complexes of diclofenac with a methylb- CD and monoethanolamine and in vitro transdermal evaluation. Eur J Med Chem 45:4079-88.
23. Osborne NN. (2008). Pathogenesis of ganglion ''cell death'' in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res 173:339-52.
24. Osborne NN. (2010). Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp Eye Res 90:750-7.
25. Palma SD, Tartara LI. Quinteros D, et al. (2009). An efficient ternary complex of acetazolamide with HP-b-CD and TEA for topical ocular administration. J Control Rel 138:24-31.
26. Pignatello R, Bucolo C, Ferrara P, et al. (2002a). Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53-61.
27. Pignatello R, Bucolo C, Spedalieri G, et al. (2002b). Flurbiprofen loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23:3247-55.
28. Pignatello R, Ricupero N, Bucolo C, et al. (2006). Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 7:E1-7.
29. Sabri K, Levin AV. (2006). The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma. J Am Assoc Ped Ophth Strab 10:464-8.
30. Sanchez-Mart?nez M, da Costa Martins R, Quincoces G, et al. (2013). Radiolabeling and biodistribution studies of polymeric nanoparticles as adjuvants for ocular vaccination against brucellosis. Rev Esp Med Nucl Imagen Mo 32:92-7.
31. Sharan S, Dupuis A, Hebert D, Levin AV. (2010). The effect of oral acetazolamide on weight gain in children. Can J Ophthalmol 45: 41-5.
32. Smith BC. (1996). Fundamentals of Fourier transform infrared spectroscopy. Boca Raton (FL): CRC Pres.s.
33. Weber PA. (1981). Neovascular glaucoma. Curr Manage Surv Ophthalmol 26:149-53.
34. Yoo JW, Giri N, Lee CH. (2011). pH-Sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm 403:262-7.
35. Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. (2009). Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm 73: 102-6.
36. Zhang Y, Wu X, Meng L, et al. (2012). Thiolated eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J Pharm 436:341-50.
37. Zimmer AK, Kreuter J. (1995). Microspheres and NPs used in ocular drug delivery systems. Adv Drug Deliv Rev 16:61-73